In literature there are evidences regarding both the involvement of RANK/RANK-L/OPG in the pathogenesis of several bone tumors (i.e., osteosarcoma, giant cell tumor of bone, chondroblastoma) and the possibility to inhibit RANK-L to reduce the tumor-induced lesions of bone often observed in cancer [51]. This evidence concerns the gene TNFSF11 and cancer.